Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Severe acute exacerbations (AE) of idiopathic pulmonary fibrosis (IPF) are medically untreatable and often fatal within days. Recent evidence suggests autoantibodies may be involved in IPF progression. Autoantibody-mediated lung diseases are typically refractory to glucocorticoids and nonspecific medications, but frequently respond to focused autoantibody reduction treatments. We conducted a pilot trial to test the hypothesis that autoantibody-targeted therapies may also benefit AE-IPF patients. METHODS: Eleven (11) critically-ill AE-IPF patients with no evidence of conventional autoimmune diseases were treated with therapeutic plasma exchanges (TPE) and rituximab, supplemented in later cases with intravenous immunoglobulin (IVIG). Plasma anti-epithelial (HEp-2) autoantibodies and matrix metalloproteinase-7 (MMP7) were evaluated by indirect immunofluorescence and ELISA, respectively. Outcomes among the trial subjects were compared to those of 20 historical control AE-IPF patients treated with conventional glucocorticoid therapy prior to this experimental trial. RESULTS: Nine (9) trial subjects (82%) had improvements of pulmonary gas exchange after treatment, compared to one (5%) historical control. Two of the three trial subjects who relapsed after only five TPE responded again with additional TPE. The three latest subjects who responded to an augmented regimen of nine TPE plus rituximab plus IVIG have had sustained responses without relapses after 96-to-237 days. Anti-HEp-2 autoantibodies were present in trial subjects prior to therapy, and were reduced by TPE among those who responded to treatment. Conversely, plasma MMP7 levels were not systematically affected by therapy nor correlated with clinical responses. One-year survival of trial subjects was 46+15% vs. 0% among historical controls. No serious adverse events were attributable to the experimental medications. CONCLUSION: This pilot trial indicates specific treatments that reduce autoantibodies might benefit some severely-ill AE-IPF patients. These findings have potential implications regarding mechanisms of IPF progression, and justify considerations for incremental trials of autoantibody-targeted therapies in AE-IPF patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT01266317.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“patients with respiratory failure due to an AE-IPF showed clinical improvement after undergoing combined plasmapheresis (which would be presumed to remove offending antibodies) and anti-CD20 therapy (170).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762 · cited 2×
“[35–39] Lung histology in these acute cases is typified by the superimposed presence of diffuse alveolar damage, which is also a characteristic finding of AE-IPF.”
BackgroundMethodAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Lymphoid neogenesis in chronic inflammatory diseases
Aloisi, F., & Pujol-Borrell, R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1786 · Cited by 908
BAFF, APRIL and their receptors: Structure, function and signaling
Bossen, C., & Schneider, P. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.04.006 · Cited by 521
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Evidence‐based guidelines for the use of immunologic tests: Antinuclear antibody testing
Solomon, D. H., Kavanaugh, A. J., Schur, P. H., & American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2002) · Arthritis Care & Research · doi:10.1002/art.10561 · Cited by 510 · cited 1×
“The production of antibodies with avidities for varied self-proteins is a common feature of immunological disorders, as well as being a defining criterion of “autoimmunity”.[34] Numerous distinct autoantibodies have been found in IPF cohorts,[7–17] and one or more of these self-reactive immunoglobulins are present in…”
BackgroundIntravenous Immune Globulin in Autoimmune and Inflammatory Diseases
Gelfand, E. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1009433 · Cited by 495 · cited 1×
“IVIG is widely used in the management of other serious autoimmune disorders, as an adjunct with TPE and/or rituximab, to mitigate autoantibody rebound and/or provide additional immunomodulatory effects.[51,52] IVIG but was not employed in the first series of subjects, again due to our initial bias for conservatism giv…”
BackgroundPeripheral blood proteins predict mortality in idiopathic pulmonary fibrosis
Richards, T. J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L. J., Lindell, K. O., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0058oc · Cited by 381 · cited 10×
“[42] MMP7 determinations were performed in the plasma specimens to examine treatment effects on concentrations of a representative soluble non-autoantibody mediator that has been linked to IPF.”
BackgroundMethodSelf-citationFranks, A. L., & Slansky, J. E. (2012) · PubMed · Cited by 326
Cited by
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
“(50, 55, 66, 68, 70), and polymyxin B-immobilized fiber column perfusion (56, 71-”
Inflammation and immunity in IPF pathogenesis and treatment
Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.015 · Cited by 517
What's in a name? That which we call IPF, by any other name would act the same
Wells, A. U., Brown, K. K., Flaherty, K. R., Kolb, M., & Thannickal, V. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00692-2018 · Cited by 352
The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314
“A beneficial role of B-cell-targeted therapies is further supported by the finding that patients with respiratory failure due to an AE-IPF showed clinical improvement after undergoing combined plasmapheresis (which would be presumed to remove offending antibodies) and anti-CD20 therapy (170).”
BackgroundThe therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis
Murtha, L. A., Schuliga, M. J., Mabotuwana, N. S., Hardy, S. A., Waters, D. W., Burgess, J. K., Knight, D. A., & Boyle, A. J. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00777 · Cited by 229
“Autoantibodies produced by activated B cells may also contribute to the development of IPF (Donahoe et al., 2015).”
BackgroundAcute Exacerbation in Interstitial Lung Disease
Leuschner, G., & Behr, J. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00176 · Cited by 171
“Other studies identified a positive effect of a treatment with rituximab with plasma exchange and intravenous immunoglobulin (105), polymyxin B-immoblilized fiber column perfusion (99, 106–109), and intra-venous thrombomodulin (110–114).”
BackgroundPlasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients
Xue, J., Kass, D. J., Bon, J., Vuga, L., Tan, J., Csizmadia, E., Otterbein, L., Soejima, M., Levesque, M. C., Gibson, K. F., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203476 · Cited by 161
“, plasma exchange (23)] and/or B cell–depleting agents, including rituximab (24–27), and a preliminary report indicates this approach may also possibly benefit IPF patients (50).”
BackgroundSelf-citationPharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)
Saito, S., Alkhatib, A., Kolls, J. K., Kondoh, Y., & Lasky, J. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.62 · Cited by 148
Dysregulation of metabolic pathways in pulmonary fibrosis
Rajesh, R., Atallah, R., & Bärnthaler, T. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108436 · Cited by 139
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation
Kreuter, M., Polke, M., Walsh, S. L. F., Krisam, J., Collard, H. R., Chaudhuri, N., Avdeev, S. N., Behr, J., Calligaro, G., Corte, T. J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01760-2019 · Cited by 130
“cyclosporine A, intravenous cyclophosphamide and tacrolimus (mainly in Asia, Rituximab mostly in North and South America), although there is low or very low evidence for the use of these treatments.(21-25) Therefore, further trials are needed.”
BackgroundSchiller, H. B., Mayr, C. H., Leuschner, G., Strunz, M., Staab-Weijnitz, C., Preisendörfer, S., Eckes, B., Moinzadeh, P., Krieg, T., Schwartz, D. A., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201611-2263oc · Cited by 116
“Circulating autoantibodies in IPF have been described long time ago [6], and a causative role for B-cell mediated autoimmunity for idiopathic ILD has been discussed [42, 43].”
BackgroundMitochondrial Dysfunction in Pulmonary Fibrosis
Rangarajan, S., Bernard, K. F., & Thannickal, V. J. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201705-370aw · Cited by 116
Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.
Juarez, M. M., Chan, A. L., Norris, A., Morrissey, B. M., & Albertson, T. E. (2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.01.17 · Cited by 114
Acute exacerbation of interstitial lung disease associated with rheumatic disease
Luppi, F., Sebastiani, M., Salvarani, C., Bendstrup, E. M., & Manfredi, A. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00721-z · Cited by 95
Marchioni, A., Tonelli, R., Ball, L., Fantini, R., Castaniere, I., Cerri, S., Luppi, F., Malerba, M., Pelosi, P. P., & Clini, E. M. (2018) · Critical Care · doi:10.1186/s13054-018-2002-4 · Cited by 95
“…2012 [90]; Oishi et al., 2013 [91]; Seo et al., 2006 [92]; Tachibana et al., 2011 [93] Rituximab, plasma exchange, and intravenous immunoglobulin Donahoe et al., 2015 [94] Tacrolimus Horita et al., 2011 [95] Thrombomodulin Kataoka et al., 2015 [96]; Tsushima et al., 2014 [97]; Isshiki et al.,…”
BackgroundEmerging role of immune cells as drivers of pulmonary fibrosis
Mutsaers, S. E., Miles, T., Prêle, C. M., & Hoyne, G. F. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108562 · Cited by 96
Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis
Li, F. J., Surolia, R., Li, H., Wang, Z., Kulkarni, T., Liu, G., de Andrade, J. A., Kass, D. J., Thannickal, V. J., Duncan, S. R., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700473 · Cited by 85
“Nonetheless, recognition that autoimmune responses may contribute to IPF progression could also promote the development of mechanistically based approaches that specifically target these processes and perhaps have enhanced therapeutic efficacy (8).”
BackgroundSelf-citationRegulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
van Geffen, C., Deißler, A., Quante, M., Renz, H. E., Hartl, D., & Kolahian, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663203 · Cited by 88
“Rituximab indeed may be a viable treatment option of IPF (129, 130), and is included in 6 NIH registered clinical trials treating IPF at the time of writing (48)(2).”
BackgroundHeukels, P., van Hulst, J. A. C., van Nimwegen, M., Boorsma, C. E., Melgert, B. N., von der Thüsen, J. H., van den Blink, B., Hoek, R. A. S., Miedema, J., Neys, S. F. H., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1195-7 · Cited by 80
“Compared to a historical cohort, an improvement of gas exchange and clinical outcome was observed in IPF patients with an acute exacerbation treated with rituximab, together plasma exchange and intravenous immune globulin [15].”
ResultThe Management of Patients With Idiopathic Pulmonary Fibrosis
Spagnolo, P., Tzouvelekis, A., & Bonella, F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00148 · Cited by 72
“Donahoe and colleagues treated 11 patients with AE-IPF with plasma exchange and rituximab ± intravenous immunoglobulin (64).”
BackgroundRecent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis
Kondoh, Y., Cottin, V., & Brown, K. K. (2017) · European Respiratory Review · doi:10.1183/16000617.0050-2017 · Cited by 72
Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis
Prêle, C. M., Miles, T., Pearce, D. R., O’Donoghue, R. J. J., Grainge, C., Barrett, L. W., Birnie, K. A., Lucas, A., Baltic, S., Ernst, M., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01469-2021 · Cited by 74
Acute exacerbation of interstitial lung disease after procedures
Amundson, W. H., Racila, E. V., Allen, T. L., Dincer, E. H., Tomic, R., Bhargava, M., Perlman, D., & Kim, H. J. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.02.012 · Cited by 67
Acute and subacute idiopathic interstitial pneumonias
Taniguchi, H., & Kondoh, Y. (2016) · Respirology · doi:10.1111/resp.12786 · Cited by 61
Asai, Y., Chiba, H., Nishikiori, H., Kamekura, R., Yabe, H., Kondo, S., Miyajima, S., Shigehara, K., Ichimiya, S., & Takahashi, H. (2019) · Respiratory Research · doi:10.1186/s12931-019-1216-6 · Cited by 61
Checa, J., & Aran, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239317 · Cited by 61
Cao, M., Sheng, J., Qiu, X., Wang, D., Wang, D., Wang, Y., Xiao, Y., & Cai, H. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0960-1 · Cited by 53
Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?
Rangarajan, S., Locy, M. L., Luckhardt, T., & Thannickal, V. J. (2016) · Drugs · doi:10.1007/s40265-015-0523-6 · Cited by 56
Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis
Velagacherla, V., Mehta, C. H., Nayak, Y., & Nayak, U. Y. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120283 · Cited by 50
Huapaya, J. A., Wilfong, E. M., Harden, C., Brower, R. G., & Danoff, S. K. (2018) · European Respiratory Review · doi:10.1183/16000617.0061-2018 · Cited by 51
The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung
Florez‐Sampedro, L., Song, S., & Melgert, B. N. (2018) · Regeneration · doi:10.1002/reg2.97 · Cited by 49
“In fact, features of autoimmunity have been described for IPF and are thought to contribute to IPF exacerbation, since autoantibody-reductive therapies have been shown to improve the lung function of IPF patients during acute exacerbation (Donahoe et al., 2015).”
BackgroundBiondini, D., Balestro, E., Sverzellati, N., Cocconcelli, E., Bernardinello, N., Ryerson, C. J., & Spagnolo, P. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1724096 · Cited by 51
“With this rationale, 11 critically ill patients with AE-IPF were treated with therapeutic plasma exchange (TPE) and rituximab, supplemented in later cases with intravenous immunoglobulin (IVIG) [66].”
MethodTan, J., Tedrow, J. R., Nouraie, M. S., Dutta, J. A., Miller, D., Li, X., Yu, S., Chu, Y., Juan-Guardela, B. M., Kaminski, N., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600610 · Cited by 45
Self-citationIntravenous Immunoglobulin as Potential Adjunct Therapy for Interstitial Lung Disease
Hallowell, R. W., Amariei, D. E., & Danoff, S. K. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201603-179ps · Cited by 46
Petri, C. R., Patell, R. D., Batalini, F., Rangachari, D., & Hallowell, R. W. (2019) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2019.100834 · Cited by 49
Pharmacological management of IPF
Borie, R., Justet, A., Beltramo, G., Manali, E. D., Pradère, P., Spagnolo, P., & Crestani, B. (2016) · Respirology · doi:10.1111/resp.12778 · Cited by 42
Hozumi, H., Hasegawa, H., Miyashita, K., Yasui, H., Suzuki, Y., Kono, M., Karayama, M., Furuhashi, K., Hashimoto, D., Enomoto, N., et al. (2019) · Respirology · doi:10.1111/resp.13506 · Cited by 38
Capelozzi, V. L., Allen, T. C., Beasley, M. B., Cagle, P. T., Guinee, D., Hariri, L. P., Husain, A. N., Jain, D., Lantuéjoul, S., Larsen, B. T., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0115-sa · Cited by 37
Biologic Treatments in Interstitial Lung Diseases
Karampitsakos, Τ., Vraka, A., Bouros, D. E., Liossis, S. C., & Τzouvelekis, Α. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00041 · Cited by 39
“Finally, rituximab ± intravenous immunoglobulin showed 1-year survival benefit in a small cohort of patients with IPF undergoing acute exacerbation compared to historical controls (82).”
BackgroundIs personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
Clarke, D. L., Murray, L. A., Crestani, B., & Sleeman, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.010 · Cited by 33
Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis
Spagnolo, P., & Wuyts, W. A. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000405 · Cited by 36
Aberrant B Cell Receptor Signaling in Naïve B Cells from Patients with Idiopathic Pulmonary Fibrosis
Neys, S. F. H., Heukels, P., van Hulst, J. A. C., Rip, J., Wijsenbeek, M. S., Hendriks, R. W., & Corneth, O. B. J. (2021) · Cells · doi:10.3390/cells10061321 · Cited by 29
“It is currently disputed whether B cell-targeting therapies are beneficial for IPF patients [15,16,62], and a large trial with rituximab in CTD-ILD is currently ongoing (NCT01862926) [63].”
BackgroundAcute Exacerbation of Idiopathic Pulmonary Fibrosis
Lee, J. S., & Collard, H. R. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_17 · Cited by 27
Wang, Q., Xie, Z., Wu, Q., Jin, Z., Yang, C., & Feng, J. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001288 · Cited by 30
“The following evidence could help explain why antiinflammatory drugs are mostly ineffective in IPF: First, B cells are the antibody-producing cells of the adaptive immune system and B cell abnormalities are involved in the pathogenesis of IPF,([171]) but lung diseases involving humoral immunity mediated by B cells are…”
BackgroundMoll, S. A., Platenburg, M. G. J. P., Platteel, A. C. M., Vorselaars, A. D. M., Bonás, M. J., Roodenburg-Benschop, C., Meek, B., van Moorsel, C. H. M., & Grutters, J. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092944 · Cited by 24
“However, these studies may be difficult to realize because immunosuppressants can have a harmful effect in IPF in general [53,54].”
BackgroundPolke, M., Kondoh, Y., Wijsenbeek, M. S., Cottin, V., Walsh, S. L. F., Collard, H. R., Chaudhuri, N., Avdeev, S. N., Behr, J., Calligaro, G., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.699644 · Cited by 27
Preisendörfer, S., Ishikawa, Y., Hennen, E., Winklmeier, S., Schupp, J. C., Knüppel, L., Fernandez, I. E., Binzenhöfer, L., Flatley, A., Juan-Guardela, B. M., et al. (2022) · Cells · doi:10.3390/cells11081341 · Cited by 25
“Auto-antibodytargeted treatments, including therapeutic plasma exchange, have been beneficial in acute exacerbations of IPF [79] and a clinical phase II study is currently ongoing to evaluate the potential therapeutic efficacy of rituximab, a CD20 antibody which specifically targets B lymphocytes (ClinicalTrials.”
BackgroundKármán, J., Wang, J., Bodea, C. A., Cao, S., & Levesque, M. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248889 · Cited by 28
“B cells and plasma cells are enriched in IPF lung tissue, plasma cell gene expression is associated with faster disease progression and poorer survival [13], and some IPF patients are responsive to B cell depletion with rituximab [62].”
BackgroundCharacteristics and evaluation of acute exacerbations in chronic interstitial lung diseases
Kershaw, C. D., Batra, K., Torrealba, J. R., & Terada, L. S. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106400 · Cited by 26
Hernández‐González, F., Pietrocola, F., Cameli, P., Bargagli, E., Prieto‐González, S., Cruz, T., Mendoza, N., Rojas, M. M., Serrano, M., Agustí, A. G. N., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147554 · Cited by 19
“Interestingly, IPF progression and the occurrence of exacerbations were associated with B cell responses and B cells have the capacity to modify the pro-or anti-fibrotic lung microenvironment, thus influencing fibroblast activity [81–83].”
BackgroundNew treatment directions for IPF: current status of ongoing and upcoming clinical trials
Macagno, F., Varone, F., Leone, P. M., Mari, P., Panico, L., Berardini, L., & Richeldi, L. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1335601 · Cited by 19
“exchange in a small group of patients [83].”
BackgroundIntrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
Mills, R., Mathur, A., Nicol, L. M., Walker, J. J., Przybylski, A. A., MacKinnon, A. C., Howie, S., Wallace, W. A., Dransfield, I., & Hirani, N. (2019) · Journal of Immunology Research · doi:10.1155/2019/1845128 · Cited by 21
Treatment of acute exacerbations of interstitial lung disease
Azadeh, N., Moua, T., Baqir, M., & Ryu, J. H. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1446831 · Cited by 19
“pared to a historical control group [38].”
Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations
Kulkarni, T., Valentine, V. G., Fei, F., Tran-Nguyen, T. K., Quesada-Arias, L. D., Mkorombindo, T., Pham, H. P., Simmons, S. C., Dsouza, K. G., Luckhardt, T., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260345 · Cited by 18
“These plasma specimens were also used for HEp-2 indirect immunofluorescence assays (IFA), a simple "Gold Standard" for anti-epithelial IgG autoantibody detection and semi-quantitation, as described elsewhere [6, 8, 27].”
BackgroundMethodResultSelf-citationAcute exacerbation of interstitial lung disease in the intensive care unit
Charokopos, A., Moua, T., Ryu, J. H., & Smischney, N. J. (2022) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v11.i1.22 · Cited by 20
Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments
Luo, X., & Xiang, F. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1565 · Cited by 19
Moog, M., Hinze, C. A., Bormann, T., Aschenbrenner, F., Knudsen, L., DeLuca, D. S., Jonigk, D. D., Neubert, L., Welte, T., Gauldie, J., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100767 · Cited by 17
Nasonov, E. L., Ananyeva, L. P., & Avdeev, S. N. (2022) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2022-1 · Cited by 17
Donahoe, M. P., Valentine, V. G., Chien, N., Gibson, K. F., Raval, J. S., Saul, M. I., Xue, J., Zhang, Y., & Duncan, S. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133684 · Cited by 16
Self-citationInvestigational drugs for idiopathic pulmonary fibrosis
Varone, F., Montemurro, G., Macagno, F., Calvello, M., Conte, E. G., Intini, E., Iovene, B., Leone, P. M., Mari, P., & Richeldi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1364361 · Cited by 15
“A small subgroup of these patients exhibited improvement in gas exchange [106].”
BackgroundAn update on current and emerging drug treatments for idiopathic pulmonary fibrosis
Trachalaki, A., Sultana, N., & Wells, A. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2213436 · Cited by 15
Kulkarni, T., Criner, G. J., Kass, D. J., Rosas, I. O., Scholand, M. B., Dilling, D. F., Summer, R. S., & Duncan, S. R. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02957-3 · Cited by 16
“When this treatment was employed with fewer TPE over shorter periods, and although there was usually rapid initial benefit, fulminant relapses within 2-8 weeks were frequent [30].”
MethodResultInfluentialSelf-citationThe Management of Interstitial Lung Disease in the ICU: A Comprehensive Review
Dhanani, Z., & Gupta, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226657 · Cited by 18
Boustani, K., Ghai, P., Invernizzi, R., Hewitt, R. J., Maher, T. M., Li, Q., Molyneaux, P. L., & Harker, J. A. (2021) · ERJ Open Research · doi:10.1183/23120541.00481-2021 · Cited by 14
Novel management strategies for idiopathic pulmonary fibrosis
Ahmad, K., & Nathan, S. D. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1513332 · Cited by 18
ICU Management of the Patient With Fibrotic Interstitial Lung Disease
Krishnan, A., Janz, D. R., & Lammi, M. R. (2023) · CHEST Critical Care · doi:10.1016/j.chstcc.2023.100020 · Cited by 14
Luppi, F., Manfredi, A., Faverio, P., Franco, G., Salvarani, C., Bendstrup, E. M., & Sebastiani, M. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103668 · Cited by 17
Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
Brereton, C. J., & Jo, H. E. (2020) · Breathe · doi:10.1183/20734735.0086-2020 · Cited by 15
Obaculactone protects against bleomycin-induced pulmonary fibrosis in mice
Wang, X., Ouyang, Z., You, Q., He, S., Meng, Q., Hu, C., Wu, X., Sun, Y., Sun, Y., Xu, Q., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.05.005 · Cited by 13
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials
Sgalla, G., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1931119 · Cited by 13
The Role of Immunity and Inflammation in IPF Pathogenesis
Butler, M. W., & Keane, M. P. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_6 · Cited by 14
Idiopatic pulmonary fibrosis: A new paradigm
Avdeev, S. N. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh2017891112-122 · Cited by 13
B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents
Roman, J., & Chiba, H. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0101ed · Cited by 12
“More recently, a pilot study was conducted in which 11 critically ill patients with acute exacerbations of IPF were treated with therapeutic plasma exchanges and rituximab, which was in some cases supplemented with intravenous immunoglobulin therapy (13); nine patients showed improvements compared with one in the hist…”
BackgroundEngelbrecht, E., Kooistra, T., Burg, N. D., Hariri, L. P., Nguyen, T. H., Brazee, P. L., Hla, T., Gochuico, B. R., & Knipe, R. S. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70102 · Cited by 15
“…epithelial dysfunction, fibroblast activity and collagen deposition, which has led to FDA approval of pirfe-nidone and nintedanib for IPF [28, 29] as well as multiple agents at various stages of preclinical and clinical development targeting fibrotic pathways [30 – 35] and immune cells [36 – 38].”
Syed, M. K. H., Bruck, O., Kumar, A., & Surani, S. (2023) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v12.i3.153 · Cited by 9
Shadid, A., Rich, H. E., DeVaughn, H., Domozhirov, A. Y., Doursout, M., Mills, T., Eckel‐Mahan, K. L., Karmouty‐Quintana, H., Restrepo, M. I., & Shivshankar, P. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1479801 · Cited by 10
Development of a non-infectious rat model of acute exacerbation of idiopathic pulmonary fibrosis
Chen, S.-S., Yin, Z.-F., Chen, T., Qiu, H., Wei, Y., Du, S.-S., Jin, Y., Zhao, M., Wu, Q., Weng, D., et al. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.01.22 · Cited by 11
Isshiki, T., Sakamoto, S., & Homma, S. A. (2019) · Medicina · doi:10.3390/medicina55050172 · Cited by 9
“proposed another treatment strategy [23].”
Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF
Murray, L. A., Grainge, C., Wark, P. A. B., & Knight, D. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.003 · Cited by 12
Yoon, Y. M., Velez, T. E., Upadhyay, V., Vazquez, S. E., Lee, C. T., Selvan, K. C., Law, C. S., Blaine, K. M., Hollinger, M. K., Decker, D. C., et al. (2023) · medRxiv · doi:10.1101/2023.05.08.23289640 · Cited by 10
“antibody depletions in IPF patients with acute exacerbation(Donahoe et al., 2015).”
BackgroundInfluentialZhong, B., Zhou, J. Q., Lyu, X., Liu, H., Yuan, K., Guo, M., Duncan, S. R., & Sanders, Y. Y. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400106 · Cited by 8
Self-citationAcute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat
Kulkarni, T., & Duncan, S. R. (2019) · Current Pulmonology Reports · doi:10.1007/s13665-019-00238-7 · Cited by 8
Self-citationAcute Exacerbation of Idiopathic Pulmonary Fibrosis
Kim, D. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11454-0 · Cited by 8
Recommendations for evaluating and managing idiopathic pulmonary fibrosis
Provencher, D. M., & Jauregui, A. R. (2018) · JAAPA · doi:10.1097/01.jaa.0000544299.00459.a4 · Cited by 7
Maître, M. L., Guerrier, T., Sanges, S., Chepy, A., Collet, A., & Launay, D. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103782 · Cited by 7
Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias.
Higo, H., Ichikawa, H., Nakamura, N., Fujii, M., Matsuoka, K., Seki, S., Wada, T., Suzaki, N., Nagata, T., Arakawa, Y., et al. (2022) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v39i4.13682 · Cited by 6
“proposed a regimen of plasma exchange + rituximab + IVIG for AE of IPF, and they reported that improvements in pulmonary gas exchange after treatment were observed in 9 of 11 patients (25).”
BackgroundAcute exacerbation in fibrotic interstitial lung disease: an international working group report
Khor, Y. H., Luppi, F., Adegunsoye, A., Collins, B. F., Farrand, E. D., Montesi, S. B., Newton, C. A., Cottin, V., Johannson, K. A., Kaul, B., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag363 · Cited by 10
Humoral Immune Status in Relation to Outcomes in Patients with Idiopathic Pulmonary Fibrosis
Hoffman, T. W., van Moorsel, C. H. M., Kazemier, K. M., Biesma, D. H., Grutters, J. C., & van Kessel, D. A. (2021) · Lung · doi:10.1007/s00408-021-00488-w · Cited by 4
Acute exacerbations of interstitial lung disease: what is the best treatment?
Meyer, K. C. (2021) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v38i1.11520 · Cited by 4
“(14) that sought to reduce autoantibodies via a combination of plasma exchange, administration of rituximab, and intravenous immunoglobulin showed that some patients with AE-IPF had prolonged survival responses.”
BackgroundEgashira, R., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00459-2023 · Cited by 4
Impact of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplant Outcomes
Warrior, K., Sayad, K., O’Hara, C., & Dilling, D. F. (2024) · Transplantation · doi:10.1097/tp.0000000000004910 · Cited by 3
Acute exacerbation of idiopathic pulmonary fibrosis
Avdeev, S. N. (2018) · PULMONOLOGIYA · doi:10.18093/0869-0189-2018-28-4-469-482 · Cited by 3
Lung immune signatures define two groups of end-stage IPF patients
Cruz, T., Mendoza, N., Casas-Recasens, S., Noell, G. G., Hernández‐González, F., Frino-García, A., Alsina‐Restoy, X., Molina‐Molina, M., Rojas, M. M., Agustí, A. G. N., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02546-8 · Cited by 3
Pharmacologic Treatment of IPF
Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3
Fibrotic Signaling in the Lung
Dutta, J. A., Bahudhanapati, H., Tan, J., Goldblum, A., & Kass, D. J. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_4 · Cited by 2
Clinical trials on acute exacerbations of interstitial lung diseases
Tsiri, P., Murgolo, F., & Crestani, B. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2519861 · Cited by 2
“A small pilot study (NCT01266317) treated patients with severe AE-IPF using a protocol of plasma exchange, rituximab intravenous immunoglobulin (IVIG) and corticosteroids has shown potential benefit in AE-ILDs [45].”
Disease Risk Assessment Using a Voronoi-Based Network Analysis of Genes and Variants Scores
Chen, L., Mukerjee, G., Dorfman, R., & Moghadas, S. M. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00029 · Cited by 3
“…sclerosis (Chauhan et al., 2013)] is compared with another patient who has a risk score of 506.11 [with mutations in TINF2, a gene associated with Idiopathic pulmonary fibrosis (Donahoe et al., 2015)], the relative risk of the former to the latter is 0.22 (Table S2, Supplementary Information).”
BackgroundInfluentialNovel drug targets in idiopathic pulmonary fibrosis
Calvello, M., Flore, M. C., & Richeldi, L. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1590196 · Cited by 2
“A small subgroup of these patients exhibited improvement in gas exchange [89].”
BackgroundA 64-Year-Old Man With Multifocal Infiltrates
Werst, D., Scarpato, B. M., Callahan, S. J., & Scholand, M. B. (2021) · CHEST Journal · doi:10.1016/j.chest.2020.09.082 · Cited by 2
Metadata
- Authors
- Donahoe, M., Valentine, V. G., Chien, N., Gibson, K. F., Raval, J. S., Saul, M., Xue, J., Zhang, Y., & Duncan, S. R.
- Affiliations
- University of Pittsburgh (US)
- The University of Texas Medical Branch at Galveston (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Duncan, Steven R.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-17
- Volume
- 10
- Issue
- 6
- Pages
- e0127771
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4470587
- OpenAlex
- W567581979
- Cited by
- 125
- References
- 54
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 8 · 2023: 9 · 2022: 10 · 2021: 15 · 2020: 11 · 2019: 16 · 2018: 17 · 2017: 20 · 2016: 10 · 2015: 2
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-07-20)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- UNC Libraries
- Funders
- University of Pittsburgh
- Medical Center, University of Pittsburgh
- National Heart, Lung, and Blood Institute (HL119960, P50HL107172, R01HL119960, HL107172)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- idiopathic pulmonary fibrosis, acute exacerbation, autoantibodies, plasma exchange, rituximab, intravenous immunoglobulin, matrix metalloproteinase-7, survival, pulmonary gas exchange
- MeSH terms
- Rituximab, Aged, Aged, 80 and over, Autoantibodies, Female, Glucocorticoids, Humans, Immunologic Factors, Lung, Male, Middle Aged, Pilot Projects, Plasma Exchange, Survival Analysis, Case-Control Studies, Immunoglobulins, Intravenous, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.